Explore the vast range of titles available.

Microbial communities of the Arctic Ocean are poorly described in comparison to aquatic environments of other regions regarding their patterns of distribution and change. The present work aims to investigate free-living bacterial communities (size fraction 0.22–1.5 μm) of different Arctic seas regions, from the river discharge area to the continental slope. Illumina MiSeq metabarcoding analysis using V3–V4 region of 16S rRNA gene was employed to study the microbial diversity of 11 Arctic seawater samples, collected from the surface and near-bottom layers in the Kara and Laptev Seas in August–September 2018. Additionally, we determined environmental parameters, bacterial abundance, biomass, and respiratory activity. Redundancy analysis, Spearman’s rank correlation, and multiple linear regression analysis were used to reveal environmental factors that modulate the bacterial community structure. The differences in the free-living bacterial community composition were associated with environmental characteristics of water layers (salinity and temperature) rather than with geographical area. Although the communities from all examined sites were dominated by Gammaproteobacteria and Alphaproteobacteria followed by Flavobacteriia and Actinobacteria, they showed distinct variations in the distribution at all taxonomical levels. No archaeal taxa were observed. The distribution patterns of the quantitative parameters of total bacterial community were not associated with defined environmental characteristics.

The expected thaw depth of the foundation soil is one of the parameters influencing the selection of technical solutions of road design in the permafrost area. The purpose of this research is a quantitative assessment of the degree of influence of air temperature on thaw depth of the road foundation soil in the permafrost area. A standard formula to calculate thaw depth of melting bodies of flat symmetry obtained through a solution of the one phase Stefan problem at boundary conditions of the first kind was used for the analysis. An algorithm using an analytical formula to assess the influence of the main initial parameters and accuracy of their determination on the resulting value, the thaw depth of the soil, is proposed. The results of the calculations are presented in a graphical form displaying the influence of average air temperature and the accuracy of its setting on the thaw depth of the road foundation soil. It was determined that the degree of change in thaw depth is non-linear and depends on both the average air temperature and on the accuracy with which it is set. For every average air temperature value there is a specific measure of required accuracy for thermal calculations so that the error of thaw depth determination does not exceed the permitted error. A 3D chart showing the expected percentage error in thaw depth forecasting depending on the average air temperature and the accuracy of its setting for an array of initial values was created.

The seasonal temperature and humidity regime of the road foundation in the active layer of soil largely determines the reliability and safety of the automobile road use. The aim of this article is a quantitative assessment of the influence of variation in ice content in the active layer of the road foundation soil in the permafrost area on the depth of seasonal soil thawing. Analytical solutions of one-phase flat Stefan problem at varying ice content along the coordinate were obtained. The solution is in the dimensionless form as a Fourier function based on Stefan number and dimensionless simplexes. The dependence of ice content change on the distance was assumed to be linear. Calculations using the obtained formulas were conducted, comparing against formulas assuming that ice content is a constant. It was determined at which ice content gradient averaging the ice content does not lead to an error greater than permitted in engineering practice in determination of the thawing depth. The results of variant calculations are presented as 2D and 3D charts to assess the influence of the initial ice content in the soil and the degree of its variation over the period of road use on the thawing depth of road foundation.

The study proves the relevance of the problem of ensuring the innovative character of the development of software production quality management systems (QMS). The goal of the QMS is to ensure the sustainability of raising and maintaining a given level of software quality and achieving strategic competitive advantages of the software manufacturer as a whole. The authors present a description of existing concepts of various scientists of the world scale, and also describe in detail the conceptual apparatus of the problem. A schematic representation of the concept of \"innovative development of the quality management system of software production\" is demonstrated. The concept and principles of the paradigm and the mechanism of innovative development of the quality management system are considered. The original concept of the innovative potential of the development of the quality management system in the field of software development is original. A model of the potential of an enterprise operating in the field of software production is described, with reference to the quality management system. The uniqueness of the research consists in presenting the concept and structure of the formation of the organizational and economic mechanism for regulating the innovation potential of the QMS of software production.

Apert syndrome (AS) is characterized by craniosynostosis (premature fusion of cranial sutures) and severe syndactyly of the hands and feet. Two activating mutations, Ser-252 → Trp and Pro-253 → Arg, in fibroblast growth factor receptor 2 (FGFR2) account for nearly all known cases of AS. To elucidate the mechanism by which these substitutions cause AS, we determined the crystal structures of these two FGFR2 mutants in complex with fibroblast growth factor 2 (FGF2). These structures demonstrate that both mutations introduce additional interactions between FGFR2 and FGF2, thereby augmenting FGFR2-FGF2 affinity. Moreover, based on these structures and sequence alignment of the FGF family, we propose that the Pro-253 → Arg mutation will indiscriminately increase the affinity of FGFR2 toward any FGF. In contrast, the Ser-252 → Trp mutation will selectively enhance the affinity of FGFR2 toward a limited subset of FGFs. These predictions are consistent with previous biochemical data describing the effects of AS mutations on FGF binding. Alterations in FGFR2 ligand affinity and specificity may allow inappropriate autocrine or paracrine activation of FGFR2. Furthermore, the distinct gain-of-function interactions observed in each crystal structure provide a model to explain the phenotypic variability among AS patients.

Calcium-independent receptor of latrotoxin (CIRL) is an orphan heptahelical receptor implicated in regulation of exocytosis. To characterize molecular mechanisms of CIRL functioning, we searched for its intracellular partners using the yeast two-hybrid SR system with the cytoplasmic C-terminal fragment of CIRL as bait. One of the interacting proteins was identified as TRIP8b, a putative cytosolic adapter protein with multiple tetratricopeptide repeats. To understand functional significance of CIRL-TRIP8b interaction, we further isolated TRIP8b-interacting proteins by affinity chromatography of brain extracts on immobilized recombinant TRIP8b. Sixteen proteins were identified by mass spectrometry in the purified preparations. Clathrin and subunits of AP2 complex appeared to be the major TRIP8b-interacting proteins. Our data suggest a role of TRIP8b in receptor-mediated endocytosis.

In patients with acute coronary syndromes, low doses of rivaroxaban were effective in reducing the primary end point of death from cardiovascular causes, myocardial infarction, or stroke. Rivaroxaban also reduced overall mortality, although there was more bleeding. After an acute coronary syndrome, patients remain at risk for recurrent cardiovascular events despite standard medical therapy, including long-term antiplatelet therapy with aspirin and an adenosine diphosphate–receptor inhibitor. This risk may be related in part to excess thrombin generation that persists beyond the acute presentation in such patients. 1 As a result, there has been interest in evaluating the role of oral anticoagulants after an acute coronary syndrome. Improved cardiovascular outcomes were reported for patients who were treated with the anticoagulant warfarin in addition to aspirin. 2 However, widespread use of long-term warfarin in such patients has been limited by challenges associated . . .

Direct oral anticoagulants are the standard of care for stroke prevention in eligible patients with atrial fibrillation and atrial flutter; however, bleeding remains a significant concern, limiting their use. Milvexian is an oral Factor XIa inhibitor that may offer similar anticoagulant efficacy with less bleeding risk. LIBREXIA AF (NCT05757869) is a global phase III, randomized, double-blind, parallel-group, event-driven trial to compare milvexian with apixaban in participants with atrial fibrillation or atrial flutter. Participants are randomly assigned to milvexian 100 mg or apixaban (5 mg or 2.5 mg per label indication) twice daily. The primary efficacy objective is to evaluate if milvexian is noninferior to apixaban for the prevention of stroke and systemic embolism. The principal safety objective is to evaluate if milvexian is superior to apixaban in reducing the endpoint of International Society of Thrombosis and Hemostasis (ISTH) major bleeding events and the composite endpoint of ISTH major and clinically relevant nonmajor (CRNM) bleeding events. In total, 15,500 participants from approximately 1,000 sites in over 30 countries are planned to be enrolled. They will be followed until both 430 primary efficacy outcome events and 530 principal safety events are observed, which is estimated to take approximately 4 years. The LIBREXIA AF study will determine the efficacy and safety of the oral Factor XIa inhibitor milvexian compared with apixaban in participants with either atrial fibrillation or atrial flutter. ClinicalTrials.gov NCT05757869 LIBREXIA AF Study Design. LIBREXIA AF is a randomized, double-blind, double-dummy, parallel-group, multicenter, event-driven, active-controlled study. Approximately 15,500 participants with permanent or paroxysmal AF are being enrolled and followed until the prespecified number of endpoint events is observed. At the end of treatment visit, clinicians are encouraged to place participants on open-open label apixaban, which will be provided by the sponsor for 30 days. [Display omitted]

Despite current antiplatelet therapy, patients remain at risk of recurrent ischemic events after acute coronary syndromes (ACS), which may reflect persistently elevated thrombin generation. Factor XIa inhibition reduces thrombin generation and may improve clinical outcomes with minimal bleeding risk. Librexia ACS (ClinicalTrials.gov NCT05754957) is a Phase 3, randomized, double-blind, placebo-controlled, event-driven trial to test the efficacy and safety of milvexian, an oral, selective factor XIa inhibitor, in addition to conventional antiplatelet therapy after a recent ACS. Eligibility criteria include symptoms of spontaneous ischemia, a diagnosis of ACS and cardiac biomarker elevation indicative of myonecrosis within 7 days before randomization, along with at least 2 risk-enhancing factors. Participants are randomly assigned to oral milvexian (25 mg twice daily) or a matched placebo. Randomization is stratified according to the planned duration and type of antiplatelet therapy. The primary efficacy endpoint is the time to first occurrence of the composite of cardiovascular death, myocardial infarction (MI), or ischemic stroke that will enroll approximately 16,000 patients with follow-up until 875 events are accrued. The first major secondary endpoint is time to the first occurrence of cardiovascular death, MI, ischemic stroke, major adverse limb events, and symptomatic venous thromboembolism. The principal safety endpoint is Bleeding Academic Research Consortium 3c or 5 bleeding. The Librexia-ACS trial will determine the efficacy and safety of milvexian after ACS and will be the first trial to test whether factor XIa inhibition in addition to standard-of-care antiplatelet therapy reduces major adverse cardiovascular events without an increased risk of significant bleeding.

Milvexian is a small molecule, selective factor XIa (FXIa) inhibitor being developed as an oral anticoagulant. This study assessed the pharmacokinetics, pharmacodynamics (activated partial thromboplastin time [aPTT]), and safety of milvexian in healthy Chinese subjects. Part 1: Thirty subjects were randomly assigned 1:1:1 to receive milvexian 25 mg on Day 1 followed by 25 mg once daily (QD) on Days 5-12; milvexian 25 mg twice daily at 12-hour intervals (BID) on Days 1-8; or milvexian 100 mg BID on Days 1-8. Part 2: Ten subjects received milvexian 200 mg on Day 1 followed by 200 mg BID on Days 5-12. Plasma samples were collected for pharmacokinetics and aPTT assessments. Safety and tolerability were assessed. Milvexian was rapidly absorbed (median t of 3-4 hours after a single dose and repeated administration). Mean maximum concentrations or area under the concentration-time curve values of milvexian in plasma after single doses or BID administration of 25 mg, 100 mg, or 200 mg increased in a dose-dependent manner. Steady state conditions were achieved within 6 days of repeated administration based on milvexian trough concentration values. Mean terminal half-life values (9-10 hours) were independent of the dose. Milvexian reversibly prolonged aPTT in a manner that was directly related to milvexian dose and exposure. All milvexian regimens were safe and well tolerated, with only mild treatment-emergent adverse events and no clinically significant bleeding events. No new safety signals were identified. The pharmacokinetic, pharmacodynamic, and safety profiles of milvexian demonstrate suitability for further clinical development in Chinese participants.